Pfizer (NYSE:PFE) recently saw the European Commission expand the authorization for its RSV vaccine, ABRYSVO, to include ...

The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report ...

Pfizer and Flagship Pioneering are turning to autoimmune disease as the sixth plank of their multibillion-dollar, 10-program ...

Trump has claimed the company delayed an announcement for its vaccine until after the 2020 presidential election.

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

The report said GSK’s former head of vaccine development, Philip Dormitzer, who joined the company after working at ...

President Trump has claimed in the past Pfizer sat on positive vaccine data, but no evidence has supported the accusation.

Pfizer's stock is cheap but faces operational challenges. Analyze its valuation and performance to make informed investment ...

(Reuters) -Federal prosecutors in Manhattan are probing a claim by GSK that Pfizer delayed announcing its COVID shot's ...

Pfizer stock slipped about 0.7% to $25.19 after The Wall Street Journal reported on an inquiry looking into the suggestion ...

Pfizer's $25 support holds strong, with institutional buying signals and growth potential in oncology. Click here to read an ...